ArticleMolecular and clinical oncology2026
Clinicopathological features and prognoses of HER-2-positive gastric cancer.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to investigate the clinicopathological characteristics of human epidermal growth factor receptor-2 (HER-2)-positive gastric cancer and their association with HER-2 protein expression levels and prognosis. In total, 99 patients diagnosed with HER-2-positive gastric cancer who underwent radical gastrectomy were included in the study. χ² testing explored the association between HER-2 protein expression and clinical features. Disease-free survival (DFS) and overall survival (OS) were evaluated through Kaplan-Meier survival curves. Univariate and multivariate Cox regression analyses were performed to evaluate the impact of clinical variables on DFS and OS. HER-2 protein expression, tumor size, tumor invasion, lymph node metastasis, Tumor-Node-Metastasis stage, perineural invasion (PNI) and lymphovascular invasion (LVI) were associated with inferior DFS. HER-2 protein expression emerged as an independent prognostic factor of DFS in HER-2-positive gastric cancer, but showed no association with OS. Compared with HER-2 immunhistochemistry (IHC) 2+ groups, patients with HER-2 IHC 3+ exhibited a higher prevalence of PNI and LVI, a shorter median DFS time, and a lower tumor-free survival rate at 1, 3 and 5 years post-surgery. In conclusion, HER-2 is a significant negative prognostic factor, associated with a poorer DFS time, although data on OS remain limited. HER-2 IHC 3+ gastric cancer is characterized by a higher prevalence of PNI and LVI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.